Ideaya Biosciences Inc
$ 28.29
-3.18%
05 Jun - close price
- Market Cap 2,485,585,000 USD
- Current Price $ 28.29
- High / Low $ 29.59 / 28.19
- Stock P/E N/A
- Book Value 10.67
- EPS -1.57
- Next Earning Report 2026-08-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.11 %
- ROE -0.14 %
- 52 Week High 39.28
- 52 Week Low 20.50
About
IDEAYA Biosciences, Inc., a synthetic precision medicine oncology company focused on lethality, is focused on the discovery and development of targeted therapies for selected patient populations using molecular diagnostics. The company is headquartered in South San Francisco, California.
Analyst Target Price
$51.69
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-17 | 2025-11-04 | 2025-08-05 | 2025-05-06 | 2025-02-13 | 2024-11-04 | 2024-08-06 | 2024-05-07 | 2024-02-20 | 2023-11-07 | 2023-08-10 |
| Reported EPS | -1.11 | -0.94 | 1.33 | -0.88 | -0.82 | -1.49 | -0.6 | -0.68 | -0.53 | -0.52 | -0.46 | -0.5 |
| Estimated EPS | -0.98 | -0.95 | -0.55 | -0.79 | -0.69 | -0.6225 | -0.63 | -0.53 | -0.5 | -0.46 | -0.5 | -0.55 |
| Surprise | -0.13 | 0.01 | 1.88 | -0.09 | -0.13 | -0.8675 | 0.03 | -0.15 | -0.03 | -0.06 | 0.04 | 0.05 |
| Surprise Percentage | -13.2653% | 1.0526% | 341.8182% | -11.3924% | -18.8406% | -139.3574% | 4.7619% | -28.3019% | -6% | -13.0435% | 8% | 9.0909% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-10 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -1.06 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IDYA
2026-06-05 17:38:57
IDEAYA Biosciences, Inc. (IDYA) Chief Development Officer Theodora Ross has reported an initial stock option holding of 297,200 shares, as detailed in a Form 3 filing. The options have an exercise price of $31.90 per share and expire on February 26, 2036. The shares will vest over four years, with 25% vesting on the first anniversary of February 23, 2026, and the remainder vesting in equal monthly installments over the subsequent three years.
2026-06-05 12:10:08
IDEAYA Biosciences recently announced positive Phase 2/3 data for darovasertib in metastatic uveal melanoma and a clinical collaboration with Roche for IDE892 in pancreatic cancer. These developments are seen as strengthening IDEAYA's precision oncology strategy and potential for broader partnerships. While darovasertib's success provides a near-term catalyst for NDA filing, the company remains unprofitable with ongoing R&D funding needs, indicating continued investment risk.
2026-06-04 05:40:16
IDEAYA Biosciences has announced a clinical collaboration with Roche to evaluate IDE892, a PRMT5 inhibitor, in combination with Roche’s pan-RAS inhibitor RG6505, for patients with pancreatic cancer. This trial will focus on patients with MTAP deletion and RAS mutation, a common genetic profile in pancreatic ductal adenocarcinoma. The collaboration aims to address the high unmet medical need in this patient population, as there are currently no approved targeted treatment options.
2026-06-04 02:40:16
Mizuho Securities has reiterated its Buy rating on IDEAYA Biosciences (IDYA.US) and maintained its price target of $50 per share. This indicates continued confidence from the firm in the biotechnology company's performance and future prospects.
2026-06-03 10:38:58
IDEAYA Biosciences announced a clinical collaboration with Roche to evaluate IDE892, a Phase 1 PRMT5 inhibitor, in combination with Roche’s pan-RAS inhibitor RG6505, for patients with pancreatic ductal adenocarcinoma featuring an MTAP deletion and RAS mutation. IDEAYA will sponsor the trial, with Roche supplying RG6505, and both companies will retain commercial rights to their respective compounds. The collaboration also includes provisions for evaluating a triplet combination involving IDE892, RG6505, and IDE397.
2026-06-03 10:38:58
IDEAYA Biosciences has announced a clinical collaboration with Roche to develop therapies for MTAP-deleted, Ras-mutant pancreatic cancer. This partnership indicates a strategic move to combine expertise in addressing a challenging form of cancer. The collaboration will likely involve clinical trials and research efforts focused on this specific cancer subtype.
